Taiwan Food and Drug Administration (FDA) is considering the use of 2’-fucosyllactose (2’-FL) fermented from two new microbial strains in all infant and toddler food products, including Foods for Special Medical Purposes (FSMPs).
Abbott has launched Similac Pro-Advance with a 2'-Fucosyllactose Oligosaccharide (2'-FL) not derived from breast milk, making it the first product in Canada with the ingredient in infant formula.
